VTGN

NASD Vistagen Therapeutics, Inc.

Nov 6, 2026 · 11:43 AM ET DELAYED Market Open

$0.1687 ↑ +0.0035 (+2.12%) Trading Up from the previous close of $0.1652, $0.0082 below the day’s high of $0.1769

YTD change: -74.51%
vs 20-day SMA: -11.21%
vs 200-day SMA: -61.27%

Price ranges

Previous day

$0.1651 $0.1809

open $0.1799 close $0.1652

-$0.0147 (-8.17%)

Today

$0.1665 $0.1769

open $0.1665 now $0.1687

+$0.0022 (+1.32%)

Past week

$0.1651 $0.1887

from $0.1707 now $0.1687

-$0.0020 (-1.17%)

Past month

$0.1651 $0.2462

from $0.2462 now $0.1687

-$0.0775 (-31.48%)

This year

$0.1651 $0.7997

from $0.6619 now $0.1687

-$0.4932 (-74.51%)

Price & Performance

-0.45 (-72.94%) / 6M

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Poor

The stock is 99.9% away from all-time highs of $123.6000
VTGN is down 75% since the beginning of the year
VTGN is down 96% over the past 12 months
VTGN is down 31% over the past 1 month
6% of all VTGN investors are betting against VTGN

VTGN reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -95.9%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No

EPS $-0.3

Earnings momentum +20.0% Quarterly EPS growth

Quarterly change +20.0%

Valuation

P/E ratio N/A

Enterprise value $-23846700.0

Beta 1.59

Balance sheet & scale

IncomeN/A

Revenue$2.5M

Cash$31.7M

Debt$783.0

Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD

Sector Professional, Scientific, and Technical Services

Industry Group Scientific Research and Development Services

Market cap $7.5M

Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company, which engages in developing and commercializing medication and treatment for anxiety, depression, and other central nervous system disorders. Its product portfolio includes Fasedienol (PH94B) nasal spray for social anxiety disorder, Itruvone (PH10) nasal spray for depression disorders, AV-101 oral NMDR glycine site antagonist for depression and neurological disorders, PH15 acute treatment for improvement of cognition, PH80 acute management of vasomotor symptoms due to menopause, and PH284 acute management of Wasting syndrome (Cachexia). The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.

Competitor comparison

Ticker	Company	Price	Change
AMGN	Amgen Inc.	$460.28	-3.80%
MRNA	Moderna, Inc.	$241.46	-6.55%
RVMD	Revolution Medicines, Inc.	$177.65	-11.04%
ROIV	Roivant Sciences Ltd.	$36.62	-4.21%
BNTX	BioNTech SE Sponsored ADR	$85.86	-5.34%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.